Australian Clinical Labs Limited News - ACL

Alchemia Limited slammed 53%: Is the stock a buy?

http://www.fool.com.au/2015/05/29/alchemia-limited-slammed-53-is-the-stock-a-buy/

Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer

Alchemia Limited (ASX:ACL), today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug...

UPDATE: Dr Reddy's Gets US OK For Generic Anticlotting Injection

Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received U.S. regulatory approval to launch a copy of GlaxoSmithKline PLC's (GSK...

Dr. Reddy’s Announces the USFDA Approval of Fondaparinux Sodium Injection

Dr. Reddy’s Laboratories (NYSE: RDY) and Alchemia Limited, Brisbane, Australia (ASX: ACL) announced today that Dr. Reddy’s has...

Dr Reddy's Gets US OK To Sell Generic Injection To Prevent Blood Clots

Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received final approval from the U.S. Food and Drug Administration to sell a...

Alchemia to Present at Cowen and Company 31st Annual Health Care Conference

Alchemia Limited (ASX: ACL) announced today that Pete Smith, Chief Executive Officer, is scheduled to present a corporate update...

Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration

Alchemia (ASX:ACL) today announced the agreement of terms with Dr Reddy’s Limited for marketing fondaparinux sodium for injection...

Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer

Alchemia’s (ASX: ACL) subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research...

Emisphere Technologies and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen® Technology

Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) today announced that they are joining efforts to develop an...

CORRECT: Alcon 3Q Profit Down 18%, Raises 2009 Earnings View

("Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time," published at 6:12 p.m. EDT, incorrectly included a tax benefit for the latest...

Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time

Alcon Inc.'s (ACL) third-quarter profit dropped 18% as foreign-exchange rates took a toll, but the eye-care products giant again raised its 2009...

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

-- Alcon takes over development of POT-4 as a treatment for patients with age-related macular degeneration -- Deal provides path for Alcon to...

NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference

Presentation to be Webcast on September 29, 2009 EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-AMEX:...

Nestle Sees No Acquisition Opportunities, Alcon Options Eyed

Nestle S.A. (NESN.VX) doesn't sees any acquisition opportunities at present, an official said Wednesday. "There's nothing available at the right...

Nestle: No Need To Renegotiate Alcon Terms With Novartis

Nestle SA (NESN.VX) said Monday it sees no reason to renegotiate deal terms on eyecare company Alcon Inc. (ACL) with Swiss drugmaker Novartis AG...

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Australian Clinical Labs Limited (ACL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ACL News

Alchemia Limited slammed 53%: Is the stock a buy?

Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer

UPDATE: Dr Reddy's Gets US OK For Generic Anticlotting Injection

Dr. Reddy’s Announces the USFDA Approval of Fondaparinux Sodium Injection

Dr Reddy's Gets US OK To Sell Generic Injection To Prevent Blood Clots

Alchemia to Present at Cowen and Company 31st Annual Health Care Conference

Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration

Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer

Emisphere Technologies and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen® Technology

CORRECT: Alcon 3Q Profit Down 18%, Raises 2009 Earnings View

Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference

Nestle Sees No Acquisition Opportunities, Alcon Options Eyed

Nestle: No Need To Renegotiate Alcon Terms With Novartis

ACL Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Australian Clinical Labs Limited (ACL) News

Australian Clinical Labs Limited (ACL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ACL News

Alchemia Limited slammed 53%: Is the stock a buy?

Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer

UPDATE: Dr Reddy's Gets US OK For Generic Anticlotting Injection

Dr. Reddy’s Announces the USFDA Approval of Fondaparinux Sodium Injection

Dr Reddy's Gets US OK To Sell Generic Injection To Prevent Blood Clots

Alchemia to Present at Cowen and Company 31st Annual Health Care Conference

Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration

Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer

Emisphere Technologies and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen® Technology

CORRECT: Alcon 3Q Profit Down 18%, Raises 2009 Earnings View

Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference

Nestle Sees No Acquisition Opportunities, Alcon Options Eyed

Nestle: No Need To Renegotiate Alcon Terms With Novartis

ACL Discussion

Your Recent History

Company

Business

Popular

Get The App